Bristol-Myers Squibb to Post Select Investigational Compound Data Updates on Company Website

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) will begin posting updates about select Phase 1 and 2 investigational compounds on the company website at www.bms.com/research/investigational. The updates will communicate an overview of new data presented at medical meetings or data published in scientific journals. The first update will be posted on Saturday, April 17, 2010.

Media and investors interested in receiving notifications when investigational compound updates are posted may subscribe to Bristol-Myers Squibb’s “Investigational Compound News” RSS feed at www.bms.com/news/pages/rss_alerts.aspx.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com.



CONTACT:

Bristol-Myers Squibb Company
Media:
Sonia Choi, 609-252-5132
[email protected]
or
Investors:
John Elicker, 609-252-4611
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical  Other Health  General Health

MEDIA:

Logo
 Logo

Suggested Articles

A phase 1/2b test showed Roche's antibody mosunetuzumab can trigger durable responses in a significant minority of hard-to-treat NHL patients.

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.